View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2016	Jul. 29, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Emergent BioSolutions Inc.
Entity Central Index Key	0001367644
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		40,458,718
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 333,395	$ 312,795
Accounts receivable, net	66,749	120,767
Inventories	96,674	76,936
Income tax receivable, net	9,184	6,573
Prepaid expenses and other current assets	22,045	20,339
Total current assets	528,047	537,410
Property, plant and equipment, net	359,034	331,856
In process research and development	41,800	42,501
Intangible assets, net	52,645	57,375
Goodwill	54,902	54,902
Deferred tax assets, net	18,192	11,286
Other assets	1,846	2,154
Total assets	1,056,466	1,037,484
Current liabilities:
Accounts payable	58,974	45,966
Accrued expenses and other current liabilities	2,482	6,229
Accrued compensation	29,778	34,683
Contingent consideration, current portion	2,983	2,553
Provision for chargebacks	2,512	2,238
Deferred revenue, current portion	7,129	7,942
Total current liabilities	103,858	99,611
Contingent consideration, net of current portion	22,580	23,046
Long-term indebtedness	247,393	246,892
Deferred revenue, net of current portion	8,410	6,590
Other liabilities	1,553	1,328
Total liabilities	383,794	377,467
Stockholders' equity:
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at both June 30, 2016 and December 31, 2015	0	0
Common stock, $0.001 par value; 200,000,000 shares authorized, 40,852,511 shares issued and 40,429,681 shares outstanding at June 30, 2016; 100,000,000 shares authorized, 39,829,408 shares issued and 39,406,578 shares outstanding at December 31, 2015	41	40
Treasury stock, at cost, 422,830 common shares at both June 30, 2016 and December 31, 2015	(6,420)	(6,420)
Additional paid-in capital	337,947	317,971
Accumulated other comprehensive loss	(3,080)	(2,713)
Retained earnings	344,184	351,139
Total stockholders' equity	672,672	660,017
Total liabilities and stockholders' equity	$ 1,056,466	$ 1,037,484

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	100,000,000
Common stock, shares issued (in shares)	40,852,511	39,829,408
Common stock, shares outstanding (in shares)	40,429,681	39,406,578
Treasury stock ( in shares)	422,830	422,830

Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2016

Jun. 30, 2015

Jun. 30, 2016

Jun. 30, 2015

Revenues:

Product sales

$ 58,546

$ 82,023

$ 130,252

$ 100,314

Contract manufacturing

10,156

8,859

17,743

21,102

Contracts, grants and collaborations

32,785

35,230

64,494

68,329

Total revenues

101,487

126,112

212,489

189,745

Operating expenses:

Cost of product sales and contract manufacturing

35,612

27,266

64,115

46,014

Research and development

35,347

40,941

69,501

79,643

Selling, general and administrative

44,148

36,453

83,932

70,946

Income (loss) from operations

(13,620)

21,452

(5,059)

(6,858)

Other income (expense):

Interest income

220

273

406

355

Interest expense

(1,509)

(1,628)

(3,033)

(3,288)

Other income, net

(497)

133

(397)

Total other expense, net

(1,272)

(1,852)

(2,494)

(3,330)

Income (loss) before provision for (benefit from) income taxes

(14,892)

19,600

(7,553)

(10,188)

Provision for (benefit from) income taxes

(3,945)

5,500

(597)

(2,769)

Net income (loss)

$ (10,947)

$ 14,100

$ (6,956)

$ (7,419)

Net income (loss) per share - basic

$ (0.27)

$ 0.37

$ (0.17)

$ (0.19)

Net income (loss) per share-diluted

$ (0.27)

^[1]

$ 0.32

^[1]

$ (0.17)

$ (0.19)

Weighted-average number of shares - basic (in shares)

40,202,821

38,480,754

39,872,738

38,216,524

Weighted-average number of shares - diluted (in shares)

40,202,821

47,410,413

39,872,738

38,216,524

[1]	See Note 8 "Earnings per share" for details on calculation.

Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Consolidated Statements of Comprehensive Income (Loss) (Unaudited) [Abstract]
Net income (loss)	$ (10,947)	$ 14,100	$ (6,956)	$ (7,419)
Foreign currency translations, net of tax	1,072	(415)	(367)	(649)
Comprehensive income (loss)	$ (9,875)	$ 13,685	$ (7,323)	$ (8,068)

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net income (loss)	$ (6,956)	$ (7,419)
Adjustments to reconcile to net cash provided by (used in) operating activities:
Stock-based compensation expense	9,945	7,790
Depreciation and amortization	17,770	17,298
Income taxes	547	630
Change in fair value of contingent obligations	935	751
Impairment of long-lived assets	1,114	0
Excess tax benefits from stock-based compensation	(10,442)	(7,241)
Other	775	153
Changes in operating assets and liabilities:
Accounts receivable	53,933	(40,884)
Inventories	(19,738)	(19,034)
Income taxes	(14,556)	(16,740)
Prepaid expenses and other assets	(1,713)	2,465
Accounts payable	11,287	2,062
Accrued expenses and other liabilities	(3,533)	157
Accrued compensation	(4,966)	(5,473)
Provision for chargebacks	274	(253)
Deferred revenue	1,007	2,368
Net cash provided by (used in) operating activities	35,683	(63,370)
Cash flows from investing activities:
Purchases of property, plant and equipment	(39,246)	(19,681)
Net cash used in investing activities	(39,246)	(19,681)
Cash flows from financing activities:
Proceeds from other long-term debt obligations	0	2,000
Issuance of common stock upon exercise of stock options	14,524	13,162
Excess tax benefits from stock-based compensation	10,442	7,241
Contingent obligation payments	(971)	(5,002)
Net cash provided by financing activities	23,995	17,401
Effect of exchange rate changes on cash and cash equivalents	168	(8)
Net increase (decrease) in cash and cash equivalents	20,600	(65,658)
Cash and cash equivalents at beginning of period	312,795	280,499
Cash and cash equivalents at end of period	$ 333,395	$ 214,841

Summary of significant accounting policies	6 Months Ended
Summary of significant accounting policies	Jun. 30, 2016
Summary of significant accounting policies [Abstract]
Summary of significant accounting policies	1. Summary of significant accounting policies Basis of presentation and consolidation On August 6, 2015, Emergent BioSolutions Inc. (the "Company" or "Emergent"), announced its plan to separate into two independent publicly-traded companies, one a biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients' lives and the other a global specialty life sciences company focused on providing specialty products for civilian and military populations that address intentional and naturally emerging public health threats. In accordance with the separation plan, Emergent transferred certain assets and liabilities of its biosciences business into Aptevo Therapeutics Inc. ("Aptevo"), a wholly-owned subsidiary of Emergent before the completion of the spin-off, which was incorporated in February 2016. In anticipation of the spin-off, the Company realigned certain components of its biosciences business to the new Aptevo segment to be consistent with how the Company's chief operating decision maker ("CODM") allocates resources and makes decisions about the operations of the Company. Effective January 1, 2016, the Company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation. On August 1, 2016, the Company completed the spin-off of Aptevo. Aptevo is now an independent public company trading under the symbol "APVO" on the NASDAQ Global Select Market ("NASDAQ"). The accompanying unaudited financial statements for the three months and six months ended June 30, 2016 and 2015 include the results of Aptevo. The spin-off of Aptevo has therefore not yet been reflected in the Company's historical results and will be presented as a discontinued operation beginning in the third quarter of 2016. Discontinued operations will reflect the revenues and expenses directly associated with the results of operations of Aptevo for all periods presented. The accompanying unaudited consolidated financial statements include the accounts of Emergent and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the SEC. During the six months ended June 30, 2016, there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the SEC. In the opinion of the Company's management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to present fairly the financial position of the Company as of June 30, 2016; the results of operations and comprehensive income (loss) for the three and six months ended June 30, 2016 and 2015; and cash flows for the six months ended June 30, 2016 and 2015. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.

Fair value measurements

6 Months Ended

Jun. 30, 2016

Fair value measurements [Abstract]

Fair value measurements

2. Fair value measurements

The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	June 30, 2016
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	92	$	-	$	-	$	92
Total assets		$	92	$	-	$	-	$	92

Liabilities:
Contingent consideration		$	-	$	-	$	25,563	$	25,563
Total liabilities		$	-	$	-	$	25,563	$	25,563

	December 31, 2015
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	3,323	$	-	$	-	$	3,323
Total assets		$	3,323	$	-	$	-	$	3,323

Liabilities:
Contingent consideration		$	-	$	-	$	25,599	$	25,599
Total liabilities		$	-	$	-	$	25,599	$	25,599

(1) Included in cash and cash equivalents in the accompanying consolidated balance sheets.

During the six months ended June 30, 2016, the Company did not have any transfers between Level 1 and Level 2 assets or liabilities.

The fair value of contingent consideration obligations are based on management's assessment of certain development and regulatory milestones, along with updates in the assumed achievement of potential future net sales for the EV-035 series of molecules and the broad spectrum antiviral platform program, which are inputs that have no observable market (Level 3). For both the three and six months ended June 30, 2016, the contingent consideration obligation decreased by $0.4 million. For the three months ended June 30, 2015, the contingent consideration obligation decreased by $0.4 million. For the six months ended June 30, 2015, the contingent consideration obligation increased by $0.4 million. These changes are primarily due to the estimated timing and probability of success for certain development and regulatory milestones and the estimated timing and volume of potential future sales of EV-035 series of molecules and the broad spectrum antiviral platform, along with the novation of the DTRA contract for the EV-035 series of molecules. These decreases and increases in the contingent consideration were classified in the Company's statement of operations as both selling, general and administrative and research and development expense. During the six months ended June 30, 2015, the Company received novation of the DTRA contract and paid the $4.0 million milestone to Evolva in the second quarter of 2015.

The fair value of the RSDL and HepaGam contingent consideration obligations changed as a result of management's assessment of the assumed and actual achievement of future net sales, which are inputs that have no observable market (Level 3). For the three and six months ended June 30, 2016, the contingent purchase consideration obligations increased by $0.5 million and $1.3 million, respectively. For the three months ended June 30, 2015, the contingent consideration obligation decreased by $0.4 million. For the six months ended June 30, 2015, the contingent consideration obligation increased by $0.4 million. The increases and decreases are primarily due to an adjustment to the actual and expected timing and volume of RSDL and HepaGam B sales. These changes are classified in the Company's statement of operations as cost of product sales and contract manufacturing.

The following table is a reconciliation of the beginning and ending balance of the liabilities, consisting only of contingent consideration, measured at fair value using significant unobservable inputs (Level 3) during the six months ended June 30, 2016.

(in thousands)
Balance at December 31, 2015	$	25,599
Expense included in earnings		935
Settlements		(971	)
Purchases, sales and issuances		-
Transfers in/(out) of Level 3		-
Balance at June 30, 2016	$	25,563

Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. As of June 30, 2016, the in-process research and development asset for EV-035 series of molecules was measured at fair value on a non-recurring basis.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Inventories

6 Months Ended

Jun. 30, 2016

Inventories [Abstract]

Inventories

3. Inventories

Inventories consisted of the following:

	June 30,		December 31,
(in thousands)	2016		2015
Raw materials and supplies	$	27,875	$	23,099
Work-in-process		41,281		37,209
Finished goods		27,518		16,628
Total inventories	$	96,674	$	76,936

Property, plant and equipment

6 Months Ended

Jun. 30, 2016

Property, plant and equipment [Abstract]

Property, plant and equipment

4. Property, plant and equipment

Property, plant and equipment consisted of the following:

	June 30,			December 31,
(in thousands)	2016			2015
Land and improvements	$	17,208		$	16,520
Buildings, building improvements and leasehold improvements		142,687			111,060
Furniture and equipment		201,455			136,528
Software		56,716			39,784
Construction-in-progress		51,097			127,489
Property, plant and equipment, gross		469,163			431,381
Less: Accumulated depreciation and amortization		(110,129	)		(99,525	)
Total property, plant and equipment, net	$	359,034		$	331,856

Intangible assets, in-process research and development

6 Months Ended

Jun. 30, 2016

Intangible assets and in-process research and development [Abstract]

Intangible assets, in-process research and development

5. Intangible assets and in-process research and development

As of June 30, 2016, $41.8 million of IPR&D assets related to the Company's otlertuzumab product candidate is included in the Aptevo segment.

Intangible assets consisted of the following:

	Biodefense			Aptevo
(in thousands)	Segment			Segment			Total
Cost basis
Balance at December 31, 2015	$	55,790		$	20,809		$	76,599
Additions		-			-			-
Balance at June 30, 2016	$	55,790		$	20,809		$	76,599

Accumulated amortization
Balance at December 31, 2015	$	(15,857	)	$	(3,368	)	$	(19,225	)
Amortization		(3,557	)		(1,172	)		(4,729	)
Balance at June 30, 2016	$	(19,414	)	$	(4,540	)	$	(23,954	)

Net balance at June 30, 2016	$	36,376		$	16,269		$	52,645

Amortization expense consisted of the following:

	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2016		2015		2016		2015

Biodefense segment	$	1,778	$	2,014	$	3,557	$	3,777
Aptevo segment		587		378		1,172		757
Total amortization expense	$	2,365	$	2,392	$	4,729	$	4,534

As of June 30, 2016, the weighted average amortization period remaining for intangible assets in the Biodefense and Aptevo segments was 81 and 91 months, respectively.

In July 2016, the Company determined the pending spin-off of Aptevo was a potential indicator of impairment for the definite-lived intangible assets, in-process research and development indefinite-lived intangible assets and the goodwill within the Aptevo reporting unit. The Company completed an undiscounted cash flow recoverability test for the definite-lived intangibles and qualitative assessments for the indefinite-lived intangible assets, as well as the reporting unit and concluded that there was no impairment.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Long-term debt	6 Months Ended
Long-term debt	Jun. 30, 2016
Long-term debt [Abstract]
Long-term debt	6. Long-term debt In April 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30), which simplifies the presentation of debt issuance costs. ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. Prior to the issuance of ASU 2015-03, debt issuance costs were required to be presented as an asset on the balance sheet. ASU 2015-03 is effective for interim and annual periods beginning after December 15, 2015. As of December 31, 2015, the Company reclassified debt issuance costs of $1.2 million and $4.9 million from prepaid expenses and other current assets and other assets, respectively, as a reduction to long-term debt. On January 29, 2014, the Company issued $250.0 million aggregate principal amount of 2.875% Convertible Senior Notes due 2021 (the "Notes"). The Notes mature on January 15, 2021, unless earlier purchased by the Company or converted. The conversion rate is equal to 30.8821 shares of common stock per $1,000 principal amount of notes (which is equivalent to a conversion price of approximately $32.38 per share of common stock). The conversion rate is subject to adjustment upon the occurrence of certain specified events but will not be adjusted for accrued and unpaid interest. As of August 1, 2016, certain conversion features were triggered due to the completion of the Aptevo spin-off. The conversion rate under the Notes will be adjusted in accordance with the terms of the indenture, with the ten-trading day valuation period contemplated by the indenture commencing August 1, 2016. The new conversion rate will be determined and announced promptly following the end of the ten-trading day valuation period.

Equity awards

6 Months Ended

Jun. 30, 2016

Equity awards [Abstract]

Equity awards

7. Equity

As of June 30, 2016, the Company had two active stock-based employee compensation plans, the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "2006 Plan") and the Emergent BioSolutions Employee Stock Option Plan (the "2004 Plan"). The Company refers to both plans together as the "Emergent Plans."

The following is a summary of stock option award activity under the Emergent Plans:

	2006 Plan					2004 Plan
	Number of Shares			Weighted-Average Exercise Price		Number of Shares			Weighted-Average Exercise Price		Aggregate Intrinsic Value
Outstanding at December 31, 2015		2,964,237		$	22.73		29,699		$	10.28	$	52,119,607
Granted		391,158		$	33.83		-		$	-
Exercised		(700,605	)	$	19.32		(29,699	)	$	10.28
Forfeited		(24,467	)	$	26.76		-		$	-
Outstanding at June 30, 2016		2,630,323		$	25.25		-		$	-	$	10,318,273
Exercisable at June 30, 2016		1,479,516		$	21.55		-		$	-	$	9,850,228

The following is a summary of restricted stock unit award activity under the 2006 Plan:

	Number of Shares			Weighted-Average Grant Price		Aggregate Intrinsic Value
Outstanding at December 31, 2015		889,004		$	26.86	$	35,569,048
Granted		470,911		$	34.53
Vested		(404,585	)	$	24.77
Forfeited		(26,103	)	$	30.95
Outstanding at June 30, 2016		929,227		$	31.53	$	26,129,863

On May 19, 2016, at the Company's annual meeting, the shareholders approved the issuance of 3.8 million shares under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, none of which have been issued. In addition, the shareholders approved an increase in the number of authorized shares of common stock to 200 million shares.

On July 14, 2016, the Company's board of directors authorized management to repurchase, from time to time, up to an aggregate of $50 million of the Company's common stock under a board-approved share repurchase program. The timing, amount, and price of any repurchases will be made pursuant to one or more 10b5-1 plans. The term of the board authorization of the repurchase program is until December 31, 2017. The plan will permit shares to be repurchased when the Company might otherwise be precluded from doing so under insider trading laws. The repurchase program may be suspended or discontinued at any time. Any repurchased shares will be available for use in connection with Emergent's stock plans and for other corporate purposes.

In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718). ASU 2016-09 simplifies several aspects of the accounting for share-based payment award transactions, including: (1) the income tax consequences, (2) classification of awards as either equity or liabilities, and (3) classification on the statement of cash flows. ASU 2016-09 is effective for the annual reporting period beginning after December 15, 2016, including interim periods within that reporting period, with early adoption permitted. The Compnay is currently evaluating the impact that the adoption of ASU 2016-09 will have on the consolidated financial statements and related disclosures.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Earnings per share

6 Months Ended

Jun. 30, 2016

Earnings per share [Abstract]

Earnings per share

8. Earnings per share

The following table presents the calculation of basic and diluted net income (loss) per share:

	Three Months Ended June 30,					Six Months Ended June 30,
(in thousands, except share and per share data)	2016			2015		2016			2015
Numerator:
Net income (loss)	$	(10,947	)	$	14,100	$	(6,956	)	$	(7,419	)
Interest expense, net of tax		-			809		-			-
Amortization of debt issuance costs, net of tax		-			219		-			-
Net income (loss), adjusted	$	(10,947	)	$	15,128	$	(6,956	)	$	(7,419	)

Denominator:
Weighted-average number of shares—basic		40,202,821			38,480,754		39,872,738			38,216,524
Dilutive securities—equity awards		-			1,209,134		-			-
Dilutive securities—convertible debt		-			7,720,525		-			-
Weighted-average number of shares—diluted		40,202,821			47,410,413		39,872,738			38,216,524

Net income (loss) per share-basic	$	(0.27	)	$	0.37	$	(0.17	)	$	(0.19	)
Net income (loss) per share-diluted	$	(0.27	)	$	0.32	$	(0.17	)	$	(0.19	)

For the three and six months ended June 30, 2016 and 2015, basic earnings per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period.

For the three months ended June 30, 2015, diluted earnings per share is computed using the "if-converted" method by dividing the net income adjusted for interest expense and amortization of debt issuance cost, both net of tax, associated with the Company's 2.875% convertible Senior notes due 2021 (the "Notes") by the weighted average number of shares of common stock outstanding during the period. The weighted average number of shares is adjusted for the potential dilutive effect of the exercise of stock options and the vesting of restricted stock units along with the assumption of the conversion of the Notes, at the beginning of the period.

For the three and six months ended June 30, 2016 and the six months ended June 30, 2015, basic and diluted earnings per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. No adjustment to the net loss was computed under the "if-converted" method as the effect would have been anti-dilutive.

For both the three and six months ended June 30, 2016, outstanding equity awards to purchase approximately 3.5 million, respectively, shares of common stock were excluded from the calculation of diluted earnings per share. For the six months ended June 30, 2015, outstanding equity awards to purchase approximately 4.7 million shares of common stock were excluded from the calculation of diluted earnings per share. In addition, for both the three and six months ended June 30, 2016 and the six months ended June 30, 2015, approximately 7.7 million shares of common stock related to the Company's Notes were excluded from the calculation of diluted earnings per share. All outstanding equity awards to purchase common stock and shares of common stock related to the Company's Notes were excluded from the calculation of diluted earnings per share in the periods in which the Company incurred a net loss.

Related party transactions	6 Months Ended
Related party transactions	Jun. 30, 2016
Related party transactions [Abstract]
Related party transactions	9. Related party transactions In November 2015, the Company entered into a consulting arrangement with a member of the Company's Board of Directors, amended in July 2016, to provide assistance in connection with the planned spin-off of Aptevo. The total compensation under the agreement was approximately $0.2 million. The consulting agreement terminated on August 1, 2016.

Segment information

6 Months Ended

Jun. 30, 2016

Segment information [Abstract]

Segment information

10. Segment information

On August 6, 2015, the Company announced its plan to separate into two independent publicly-traded companies, one a biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients' lives and the other a global specialty life sciences company focused on providing specialty products for civilian and military populations that address intentional and naturally emerging public health threats. In anticipation of the spin-off, the Company realigned certain components of its biosciences business to the new Aptevo segment. Effective January 1, 2016, the Company changed its segment presentation to reflect this new structure, and prior periods have been recast to conform to the new presentation.

For financial reporting purposes, the Company reports financial information for two business segments: Biodefense and Aptevo. The Company's two business segments, or divisions, engage in business activities for which discrete financial information is provided to and resources are allocated by the CODM. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company's reportable segments offer different products, product candidates, manufacturing processes and services, development processes, sales and marketing processes, and are managed separately.

The Biodefense division consists of three business units: vaccines and therapeutics, medical devices and contract manufacturing. Revenues in this segment are primarily from sales of the Company's FDA-licensed product, BioThrax® (Anthrax Vaccine Adsorbed), to the U.S. government. The Aptevo division consists of one business unit, which is focused on: the discovery, development, commercialization and sale of novel oncology and hematology therapeutics.

	Reportable Segments
(in thousands)	Biodefense			Aptevo			Total
Three Months Ended June 30, 2016
External revenue	$	91,254		$	10,233		$	101,487
Intersegment revenue (expense)		1,844			(1,844	)		-
Income (loss) from operations		(1,323	)		(12,297	)		(13,620	)
Three Months Ended June 30, 2015
External revenue	$	119,022		$	7,090		$	126,112
Intersegment revenue (expense)		2,130			(2,130	)		-
Income (loss) from operations		41,694			(20,242	)		21,452

Six Months Ended June 30, 2016
External revenue	$	194,223		$	18,266		$	212,489
Intersegment revenue (expense)		2,418			(2,418	)		-
Income (loss) from operations		21,693			(26,752	)		(5,059	)
Total assets		945,058			111,408			1,056,466
Six Months Ended June 30, 2015
External revenue	$	171,169		$	18,576		$	189,745
Intersegment revenue (expense)		2,234			(2,234	)		-
Income (loss) from operations		23,198			(30,056	)		(6,858	)
Total assets		820,503			122,820			943,323

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Subsequent Event	6 Months Ended
Subsequent Event	Jun. 30, 2016
Subsequent Event [Abstract]
Subsequent Event	11. Subsequent events Aptevo On August 1, 2016, the Company completed the previously announced spin-off through the distribution of 100% of the outstanding common stock of Aptevo to the Company's shareholders (the "Distribution"). The Distribution was made to the Company's shareholders of record as of the close of business on July 22, 2016 ("Record Date"), who received one share of Aptevo common stock for every two shares of Emergent common stock held as of the Record Date. The Distribution was intended to take the form of a tax-free distribution for federal income tax purposes in the United States. As a result of the Distribution, Aptevo is now an independent public company trading under the symbol "APVO" on NASDAQ. In the aggregate, approximately 20,230,000 shares of Aptevo common stock were distributed to the Company's shareholders of record as of the Record Date in the Distribution. After giving effect to the Distribution, the Company no longer holds shares of Aptevo's common stock. In addition, on August 1, 2016, the Company entered into a non-negotiable, unsecured promissory note with Aptevo to provide up to an additional $20 million in funding within the next six to twelve months. Litigation On July 19, 2016, Plaintiff, William Sponn, or Sponn, filed a putative class action complaint in the United States District Court for the District of Maryland on behalf of purchasers of the Company's common stock between January 11, 2016 and June 21, 2016, inclusive, or the Class Period, seeking to pursue remedies under the Securities Exchange Act of 1934 against Emergent and certain of the Company's senior officers and directors, collectively, the Defendants. The complaint alleges, among other things, that the Company made materially false and misleading statements about the government's demand for BioThrax and expectations that the Company's five-year exclusive procurement contract with HHS would be renewed and omitted certain material facts. Sponn is seeking unspecified damages, including legal costs. The Defendants believe that the allegations in the complaint are without merit and intend to defend themselves vigorously against those claims. As of the date of this filing, the range of potential loss cannot be determined or estimated.

Summary of significant accounting policies (Policies)	6 Months Ended
Summary of significant accounting policies (Policies)	Jun. 30, 2016
Summary of significant accounting policies [Abstract]
Basis of presentation and consolidation	Basis of presentation and consolidation On August 6, 2015, Emergent BioSolutions Inc. (the "Company" or "Emergent"), announced its plan to separate into two independent publicly-traded companies, one a biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients' lives and the other a global specialty life sciences company focused on providing specialty products for civilian and military populations that address intentional and naturally emerging public health threats. In accordance with the separation plan, Emergent transferred certain assets and liabilities of its biosciences business into Aptevo Therapeutics Inc. ("Aptevo"), a wholly-owned subsidiary of Emergent before the completion of the spin-off, which was incorporated in February 2016. In anticipation of the spin-off, the Company realigned certain components of its biosciences business to the new Aptevo segment to be consistent with how the Company's chief operating decision maker ("CODM") allocates resources and makes decisions about the operations of the Company. Effective January 1, 2016, the Company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation. On August 1, 2016, the Company completed the spin-off of Aptevo. Aptevo is now an independent public company trading under the symbol "APVO" on the NASDAQ Global Select Market ("NASDAQ"). The accompanying unaudited financial statements for the three months and six months ended June 30, 2016 and 2015 include the results of Aptevo. The spin-off of Aptevo has therefore not yet been reflected in the Company's historical results and will be presented as a discontinued operation beginning in the third quarter of 2016. Discontinued operations will reflect the revenues and expenses directly associated with the results of operations of Aptevo for all periods presented. The accompanying unaudited consolidated financial statements include the accounts of Emergent and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the SEC. During the six months ended June 30, 2016, there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the SEC. In the opinion of the Company's management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to present fairly the financial position of the Company as of June 30, 2016; the results of operations and comprehensive income (loss) for the three and six months ended June 30, 2016 and 2015; and cash flows for the six months ended June 30, 2016 and 2015. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.

Fair value measurements (Tables)

6 Months Ended

Jun. 30, 2016

Fair value measurements [Abstract]

Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	June 30, 2016
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	92	$	-	$	-	$	92
Total assets		$	92	$	-	$	-	$	92

Liabilities:
Contingent consideration		$	-	$	-	$	25,563	$	25,563
Total liabilities		$	-	$	-	$	25,563	$	25,563

	December 31, 2015
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	3,323	$	-	$	-	$	3,323
Total assets		$	3,323	$	-	$	-	$	3,323

Liabilities:
Contingent consideration		$	-	$	-	$	25,599	$	25,599
Total liabilities		$	-	$	-	$	25,599	$	25,599

(1) Included in cash and cash equivalents in the accompanying consolidated balance sheets.

Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)

(in thousands)
Balance at December 31, 2015	$	25,599
Expense included in earnings		935
Settlements		(971	)
Purchases, sales and issuances		-
Transfers in/(out) of Level 3		-
Balance at June 30, 2016	$	25,563

Inventories (Tables)

6 Months Ended

Jun. 30, 2016

Inventories [Abstract]

Inventories

Inventories consisted of the following:

	June 30,		December 31,
(in thousands)	2016		2015
Raw materials and supplies	$	27,875	$	23,099
Work-in-process		41,281		37,209
Finished goods		27,518		16,628
Total inventories	$	96,674	$	76,936

Property, plant and equipment (Tables)

6 Months Ended

Jun. 30, 2016

Property, plant and equipment [Abstract]

Property, plant and equipment

Property, plant and equipment consisted of the following:

	June 30,			December 31,
(in thousands)	2016			2015
Land and improvements	$	17,208		$	16,520
Buildings, building improvements and leasehold improvements		142,687			111,060
Furniture and equipment		201,455			136,528
Software		56,716			39,784
Construction-in-progress		51,097			127,489
Property, plant and equipment, gross		469,163			431,381
Less: Accumulated depreciation and amortization		(110,129	)		(99,525	)
Total property, plant and equipment, net	$	359,034		$	331,856

Intangible assets, in-process research and development (Tables)

6 Months Ended

Jun. 30, 2016

Intangible assets and in-process research and development [Abstract]

Intangible Assets

Intangible assets consisted of the following:

	Biodefense			Aptevo
(in thousands)	Segment			Segment			Total
Cost basis
Balance at December 31, 2015	$	55,790		$	20,809		$	76,599
Additions		-			-			-
Balance at June 30, 2016	$	55,790		$	20,809		$	76,599

Accumulated amortization
Balance at December 31, 2015	$	(15,857	)	$	(3,368	)	$	(19,225	)
Amortization		(3,557	)		(1,172	)		(4,729	)
Balance at June 30, 2016	$	(19,414	)	$	(4,540	)	$	(23,954	)

Net balance at June 30, 2016	$	36,376		$	16,269		$	52,645

Finite-lived Intangible Assets Amortization Expense

Amortization expense consisted of the following:

	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2016		2015		2016		2015

Biodefense segment	$	1,778	$	2,014	$	3,557	$	3,777
Aptevo segment		587		378		1,172		757
Total amortization expense	$	2,365	$	2,392	$	4,729	$	4,534

As of June 30, 2016, the weighted average amortization period remaining for intangible assets in the Biodefense and Aptevo segments was 81 and 91 months, respectively.

Equity awards (Tables)

6 Months Ended

Jun. 30, 2016

Equity awards [Abstract]

Option Award Activity

The following is a summary of stock option award activity under the Emergent Plans:

	2006 Plan					2004 Plan
	Number of Shares			Weighted-Average Exercise Price		Number of Shares			Weighted-Average Exercise Price		Aggregate Intrinsic Value
Outstanding at December 31, 2015		2,964,237		$	22.73		29,699		$	10.28	$	52,119,607
Granted		391,158		$	33.83		-		$	-
Exercised		(700,605	)	$	19.32		(29,699	)	$	10.28
Forfeited		(24,467	)	$	26.76		-		$	-
Outstanding at June 30, 2016		2,630,323		$	25.25		-		$	-	$	10,318,273
Exercisable at June 30, 2016		1,479,516		$	21.55		-		$	-	$	9,850,228

Restricted Stock Units Activity

The following is a summary of restricted stock unit award activity under the 2006 Plan:

	Number of Shares			Weighted-Average Grant Price		Aggregate Intrinsic Value
Outstanding at December 31, 2015		889,004		$	26.86	$	35,569,048
Granted		470,911		$	34.53
Vested		(404,585	)	$	24.77
Forfeited		(26,103	)	$	30.95
Outstanding at June 30, 2016		929,227		$	31.53	$	26,129,863

Earnings per share (Tables)

6 Months Ended

Jun. 30, 2016

Earnings per share [Abstract]

Summary of Basic and Diluted Net Income (Loss) per Share

The following table presents the calculation of basic and diluted net income (loss) per share:

	Three Months Ended June 30,					Six Months Ended June 30,
(in thousands, except share and per share data)	2016			2015		2016			2015
Numerator:
Net income (loss)	$	(10,947	)	$	14,100	$	(6,956	)	$	(7,419	)
Interest expense, net of tax		-			809		-			-
Amortization of debt issuance costs, net of tax		-			219		-			-
Net income (loss), adjusted	$	(10,947	)	$	15,128	$	(6,956	)	$	(7,419	)

Denominator:
Weighted-average number of shares—basic		40,202,821			38,480,754		39,872,738			38,216,524
Dilutive securities—equity awards		-			1,209,134		-			-
Dilutive securities—convertible debt		-			7,720,525		-			-
Weighted-average number of shares—diluted		40,202,821			47,410,413		39,872,738			38,216,524

Net income (loss) per share-basic	$	(0.27	)	$	0.37	$	(0.17	)	$	(0.19	)
Net income (loss) per share-diluted	$	(0.27	)	$	0.32	$	(0.17	)	$	(0.19	)

Segment information (Tables)

6 Months Ended

Jun. 30, 2016

Segment information [Abstract]

Segment Information

	Reportable Segments
(in thousands)	Biodefense			Aptevo			Total
Three Months Ended June 30, 2016
External revenue	$	91,254		$	10,233		$	101,487
Intersegment revenue (expense)		1,844			(1,844	)		-
Income (loss) from operations		(1,323	)		(12,297	)		(13,620	)
Three Months Ended June 30, 2015
External revenue	$	119,022		$	7,090		$	126,112
Intersegment revenue (expense)		2,130			(2,130	)		-
Income (loss) from operations		41,694			(20,242	)		21,452

Six Months Ended June 30, 2016
External revenue	$	194,223		$	18,266		$	212,489
Intersegment revenue (expense)		2,418			(2,418	)		-
Income (loss) from operations		21,693			(26,752	)		(5,059	)
Total assets		945,058			111,408			1,056,466
Six Months Ended June 30, 2015
External revenue	$	171,169		$	18,576		$	189,745
Intersegment revenue (expense)		2,234			(2,234	)		-
Income (loss) from operations		23,198			(30,056	)		(6,858	)
Total assets		820,503			122,820			943,323

Summary of significant accounting policies (Details)	6 Months Ended
Summary of significant accounting policies (Details)	Jun. 30, 2016 Company
Summary of significant accounting policies [Abstract]
Number of independent public companies	2

Fair value measurements (Details) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2016

Jun. 30, 2015

Jun. 30, 2016

Jun. 30, 2015

Dec. 31, 2015

Dec. 17, 2014

Unobservable Input Reconciliation [Roll Forward]

Balance, beginning of period

$ 25,599

Expense included in earnings

935

Settlements

(971)

Purchases, sales and issuances

Transfers in/(out) of Level 3

Balance, end of period

$ 25,563

25,563

Evolva Holding SA 035 & Broad Spectrum Antiviral Platform [Member]

Unobservable Input Reconciliation [Roll Forward]

Change in fair value of contingent obligations

(400)

$ (400)

(400)

$ 400

Contingent value rights based on the novation of the contract

$ 4,000

RSDL and HepaGam [Member]

Unobservable Input Reconciliation [Roll Forward]

Change in fair value of contingent obligations

500

$ (400)

1,300

$ 400

Fair Value, Measurements, Recurring [Member]

Assets [Abstract]

Investment in money market funds (1)

^[1]

$ 3,323

Total assets

3,323

Liabilities [Abstract]

Contingent consideration

25,563

25,599

Total liabilities

25,563

25,599

Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]

Assets [Abstract]

Investment in money market funds (1)

^[1]

3,323

Total assets

3,323

Liabilities [Abstract]

Contingent consideration

Total liabilities

Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]

Assets [Abstract]

Investment in money market funds (1)

^[1]

Total assets

Liabilities [Abstract]

Contingent consideration

Total liabilities

Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]

Assets [Abstract]

Investment in money market funds (1)

^[1]

Total assets

Liabilities [Abstract]

Contingent consideration

25,563

25,599

Total liabilities

$ 25,563

$ 25,599

[1]	Included in cash and cash equivalents in accompanying consolidated balance sheets

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Inventories [Abstract]
Raw materials and supplies	$ 27,875	$ 23,099
Work-in-process	41,281	37,209
Finished goods	27,518	16,628
Total inventories	$ 96,674	$ 76,936

Property, plant and equipment (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 469,163		$ 431,381
Less: Accumulated depreciation and amortization	(110,129)		(99,525)
Total Property, plant and equipment, net	359,034		331,856
Depreciation and amortization	17,770	$ 17,298
Land and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	17,208		16,520
Buildings, Building Improvements and Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	142,687		111,060
Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	201,455		136,528
Software [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	56,716		39,784
Construction-in-progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 51,097		$ 127,489

Intangible assets, in-process research and development (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Cost Basis [Abstract]
Intangible Assets, Beginning Balance			$ 76,599,000
Additions			0
Intangible Assets, Ending Balance	$ 76,599,000		76,599,000
Accumulated Amortization [Abstract]
Accumulated Amortization, Beginning Balance			(19,225,000)
Amortization	2,365,000	$ 2,392,000	4,729,000	$ 4,534,000
Accumulated Amortization, Ending Balance	(23,954,000)		(23,954,000)
Net book value of intangible assets	52,645,000		52,645,000
Biodefense [Member]
Cost Basis [Abstract]
Intangible Assets, Beginning Balance			55,790,000
Additions			0
Intangible Assets, Ending Balance	55,790,000		55,790,000
Accumulated Amortization [Abstract]
Accumulated Amortization, Beginning Balance			(15,857,000)
Amortization	1,778,000	2,014,000	3,557,000	3,777,000
Accumulated Amortization, Ending Balance	(19,414,000)		(19,414,000)
Net book value of intangible assets	36,376,000		$ 36,376,000
Intangible assets, weighted average useful life			81 months
Aptevo [Member]
Cost Basis [Abstract]
Intangible Assets, Beginning Balance			$ 20,809,000
Additions			0
Intangible Assets, Ending Balance	20,809,000		20,809,000
Accumulated Amortization [Abstract]
Accumulated Amortization, Beginning Balance			(3,368,000)
Amortization	587,000	$ 378,000	1,172,000	$ 757,000
Accumulated Amortization, Ending Balance	(4,540,000)		(4,540,000)
Net book value of intangible assets	16,269,000		$ 16,269,000
Intangible assets, weighted average useful life			91 months
Aptevo [Member] \| Otlertuzumab [Member]
Accumulated Amortization [Abstract]
Net book value of intangible assets	$ 41,800,000		$ 41,800,000

Long-term debt (Details) $ / shares in Units, $ in Millions	1 Months Ended
Long-term debt (Details) $ / shares in Units, $ in Millions	Jan. 29, 2014 USD ($) shares $ / shares	Dec. 31, 2015 USD ($)
Amount of debt issuance costs in prepaid expenses and other current assets, netted against long term debt [Member]
Long-Term Debt [Line Items]
Debt issuance costs		$ 1.2
Amount of debt issuance costs in other assets, netted against long term debt [Member]
Long-Term Debt [Line Items]
Debt issuance costs		$ 4.9
Convertible Senior Notes Due 2021 [Member]
Long-Term Debt [Line Items]
Face amount of debt instrument	$ 250.0
Interest rate, stated percentage	2.875%
Maturity date	Jan. 15, 2021
Conversion rate of notes per $1,000 principal amount (in shares) \| shares	30.8821
Conversion price per share (in dollars per share) \| $ / shares	$ 32.38

Equity awards (Details)	6 Months Ended
Equity awards (Details)	Jun. 30, 2016 USD ($) Plan $ / shares shares	Jul. 14, 2016 USD ($)
Equity awards [Abstract]
Number of stock-based employee compensation plans \| Plan	2
Aggregate intrinsic value [Abstract]
Stock Repurchase Program, Authorized Amount \| $		$ 50,000,000
Stock Options Member [Member]
Aggregate Intrinsic Value [Abstract]
Outstanding, beginning of period \| $	$ 52,119,607
Outstanding, end of period \| $	10,318,273
Exercisable, end of period \| $	$ 9,850,228
2006 Plan [Member] \| Restricted Stock Units (RSUs) [Member]
Restricted stock unit award activity [Roll Forward]
Outstanding, beginning of period (in shares)	889,004
Granted (in shares)	470,911
Vested (in shares)	(404,585)
Forfeited (in shares)	(26,103)
Outstanding, end of period (in shares)	929,227
Weighted-Average Grant Price [Roll Forward]
Outstanding, beginning of period (in dollars per share) \| $ / shares	$ 26.86
Granted (in dollars per share) \| $ / shares	34.53
Vested (in dollars per share) \| $ / shares	24.77
Forfeited (in dollars per share) \| $ / shares	30.95
Outstanding, end of period (in dollars per share) \| $ / shares	$ 31.53
Aggregate intrinsic value [Abstract]
Outstanding, beginning of period \| $	$ 35,569,048
Outstanding, end of period \| $	$ 26,129,863
2006 Plan [Member] \| Stock Options Member [Member]
Options outstanding [Roll Forward]
Outstanding, beginning of period (in shares)	2,964,237
Granted (in shares)	391,158
Exercised (in shares)	(700,605)
Forfeited (in shares)	(24,467)
Outstanding, end of period (in shares)	2,630,323
Exercisable, end of period (in shares)	1,479,516
Weighted-Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share) \| $ / shares	$ 22.73
Granted (in dollars per share) \| $ / shares	33.83
Exercised (in dollars per share) \| $ / shares	19.32
Forfeited (in dollars per share) \| $ / shares	26.76
Outstanding, end of period (in dollars per share) \| $ / shares	25.25
Exercisable, end of period (in dollars per share) \| $ / shares	$ 21.55
Aggregate intrinsic value [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	3,800,000
2004 Plan [Member] \| Stock Options Member [Member]
Options outstanding [Roll Forward]
Outstanding, beginning of period (in shares)	29,699
Granted (in shares)	0
Exercised (in shares)	(29,699)
Forfeited (in shares)	0
Outstanding, end of period (in shares)	0
Exercisable, end of period (in shares)	0
Weighted-Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share) \| $ / shares	$ 10.28
Granted (in dollars per share) \| $ / shares	0
Exercised (in dollars per share) \| $ / shares	10.28
Forfeited (in dollars per share) \| $ / shares	0
Outstanding, end of period (in dollars per share) \| $ / shares	0
Exercisable, end of period (in dollars per share) \| $ / shares	$ 0

Earnings per share (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2016

Jun. 30, 2015

Jun. 30, 2016

Jun. 30, 2015

Numerator [Abstract]

Net income (loss)

$ (10,947)

$ 14,100

$ (6,956)

$ (7,419)

Interest expense, net of tax

809

Amortization of debt issuance costs, net of tax

219

Net income (loss), adjusted

$ (10,947)

$ 15,128

$ (6,956)

$ (7,419)

Denominator [Abstract]

Weighted-average number of shares-basic (in shares)

40,202,821

38,480,754

39,872,738

38,216,524

Dilutive securities-equity awards (in shares)

1,209,134

Dilutive securities-convertible debt

7,720,525

Weighted-average number of shares-diluted (in shares)

40,202,821

47,410,413

39,872,738

38,216,524

Net income (loss) per share - basic

$ (0.27)

$ 0.37

$ (0.17)

$ (0.19)

Adjusted net (loss) income per share-diluted

$ (0.27)

^[1]

$ 0.32

^[1]

$ (0.17)

$ (0.19)

Stock Options [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive shares excluded from calculation (in shares)

3,500,000

4,700,000

Convertible debt [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Interest rate percentage

2.875%

Antidilutive shares excluded from calculation (in shares)

7,700,000

[1]	See Note 8 "Earnings per share" for details on calculation.

Related party transactions (Details) $ in Millions	6 Months Ended
Related party transactions (Details) $ in Millions	Jun. 30, 2016 USD ($)
Related Party Transaction [Line Items]
Costs incurred from services rendered under marketing/consulting agreement	$ 0.2

Segment information (Details) $ in Thousands	3 Months Ended		6 Months Ended
Segment information (Details) $ in Thousands	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2016 USD ($) Company Segment BusinessUnit	Jun. 30, 2015 USD ($)	Dec. 31, 2015 USD ($)
Segment Reporting Information [Line Items]
Number of independent public companies \| Company			2
Number of business segments \| Segment			2
Income (loss) from operations	$ (10,947)	$ 14,100	$ (6,956)	$ (7,419)
Total assets	1,056,466		1,056,466		$ 1,037,484
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
External revenue	0	0	0	0
Operating Segments [Member]
Segment Reporting Information [Line Items]
External revenue	101,487	126,112	212,489	189,745
Income (loss) from operations	(13,620)	21,452	(5,059)	(6,858)
Total assets	1,056,466	943,323	1,056,466	943,323
Biodefense [Member] \| Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
External revenue	1,844	2,130	$ 2,418	2,234
Biodefense [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Number of business units \| BusinessUnit			3
External revenue	91,254	119,022	$ 194,223	171,169
Income (loss) from operations	(1,323)	41,694	21,693	23,198
Total assets	945,058	820,503	945,058	820,503
Aptevo [Member] \| Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
External revenue	(1,844)	(2,130)	$ (2,418)	(2,234)
Aptevo [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Number of business units \| BusinessUnit			1
External revenue	10,233	7,090	$ 18,266	18,576
Income (loss) from operations	(12,297)	(20,242)	(26,752)	(30,056)
Total assets	$ 111,408	$ 122,820	$ 111,408	$ 122,820

Subsequent events (Details) - Subsequent Event [Member] - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2016	Aug. 01, 2016
Subsequent Event [Line Items]
Percentage Of Outstanding Shares Distributed		100.00%
Record date for distribution	Jul. 22, 2016
Number of common stock distributed		20,230,000
Aptevo [Member]
Subsequent Event [Line Items]
Unsecured Debt - Aptevo Promissory Note		$ 20.0